LK-101 is under clinical development by Likang Life Sciences and currently in Phase II for Non-Small Cell Lung Carcinoma. According to GlobalData, Phase II drugs for Non-Small Cell Lung Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LK-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LK-101 overview

Cell therapy is under investigation for the treatment of hepatocellular carcinoma, non-small cell lung carcinoma, small-cell lung cancer and solid tumor. The personalized neoantigen based immunotherapy comprises of three courses including immature dendritic cells (DCs), cytokine-induced killer (CIK) cells and cytotoxic T lymphocytes (CTLs). DC, CIK and CTL cells are administered through intra-abdominal cavity, CIK was administered intravenously and administered through parenteral route as injection.

For a complete picture of LK-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.